Progesterone Receptor Negative Suspended Phase 1 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0038639 (Progesterone Receptor Negative)Suspended1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03012230Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast CancerTreatment